GlassScriptPhysician profile
Jon W Copeland
NPI 1265484968
$1,725.98
in general payments reported to CMS, 2019-2025
25 companies · $626 in 2025
The $626 reported for 2025 was more than what 77% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $157 · 2020: $85.21 · 2021: $156 · 2022: $319 · 2023: $231 · 2024: $152 · 2025: $626.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,009.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,009.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amneal Pharmaceuticals LLC | $344.18 | 2025 | |
| Biohorizons Implant Systems INC. | $265.48 | 2025 | Biohorizons Dental Implants |
| Novo Nordisk INC | $132.61 | 2019-2024 | Rybelsus, Ozempic, Wegovy |
| Abbott Laboratories | $116.25 | 2021-2023 | Gallant |
| Corcept Therapeutics | $99.52 | 2022 | |
| Lilly USA, LLC | $91.94 | 2020-2024 | Mounjaro |
| Astrazeneca Pharmaceuticals LP | $78.04 | 2019-2022 | |
| Glaxosmithkline, LLC. | $75.78 | 2019-2024 | Trelegy Ellipta, Arexvy |
| Janssen Pharmaceuticals, INC | $72.76 | 2023 | Xarelto, Spravato |
| Abbvie INC. | $63.18 | 2021-2022 | |
| Amgen INC. | $43.85 | 2023-2024 | Otezla, Repatha |
| Amarin Pharma, INC. | $39.21 | 2019-2022 | |
| Dexcom, INC. | $36.08 | 2022-2023 | Dexcom G6 Transmitter |
| Boehringer Ingelheim Pharmaceuticals, INC. | $33.57 | 2021-2022 | |
| Inspire Medical Systems, INC. | $32.81 | 2023-2025 | Inspire |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $31.18 | 2020-2022 | |
| Gilead Sciences, INC. | $30.47 | 2021 | |
| Pfizer INC. | $23.18 | 2024 | |
| Astellas Pharma US INC | $23.09 | 2023 | Myrbetriq |
| Si-Bone, INC. | $19.82 | 2019 | |
| Optinose US, INC. | $17.86 | 2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $15.19 | 2021 | |
| Genentech USA, INC. | $14.16 | 2019 | |
| Halozyme INC | $13.74 | 2023 | |
| Philips North America LLC | $12.03 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jon Copeland listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.